Results 121 to 130 of about 3,981,458 (213)

Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes

open access: yesJournal of Veterinary Internal Medicine
Background Romiplostim, a thrombopoietin analog, is commonly used to treat immune‐mediated thrombocytopenia (ITP) in humans, but its use in dogs remains limited.
Min‐Ok Ryu   +5 more
doaj   +1 more source

Efficacy and Safety of Apixaban Thromboprophylaxis According to Baseline Chemotherapy Class in High‐Risk Ambulatory Cancer Patients: A Post Hoc Analysis of the AVERT Trial

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancer patients. The AVERT trial showed apixaban thromboprophylaxis reduced VTE in intermediate‐to‐high‐risk patients initiating chemotherapy. However, the efficacy and safety of apixaban according to baseline chemotherapy class remain incompletely ...
Nadia Linxi Feng   +10 more
wiley   +1 more source

Hemophagocytic Lymphohistiocytosis in a Patient With Alcohol‐Associated Liver Disease: A Case Report Highlighting Diagnostic Challenges

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Hemophagocytic lymphohistiocytosis (HLH) is a life‐threatening hyperinflammatory syndrome with nonspecific clinical manifestations that can mimic common conditions in patients with alcohol dependence. Early clinical suspicion and rapid initiation of treatment are essential to prevent fatal outcomes.
Adalis Rivera   +4 more
wiley   +1 more source

Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG‐2015 French Innovative Leukemia Organization phase 2 randomized trial

open access: yesCancer, Volume 132, Issue 21, 1 November 2026.
Abstract Background Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.
Arnaud Pigneux   +24 more
wiley   +1 more source

Efficacy and Safety of Eltrombopag 25 Mg for the Management of Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumours: A Retrospective Comparative Study

open access: yesNational Board of Examinations Journal of Medical Sciences
Background: Chemotherapy-induced thrombocytopenia (CIT) can compromise chemotherapy delivery in patients with solid tumours. This study evaluated the efficacy and safety of eltrombopag 25 mg compared with standard supportive care.
Lingeshwaran S   +3 more
doaj   +1 more source

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

open access: yesHead &Neck, Volume 48, Issue 11, Page 3152-3172, November 2026.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell   +11 more
wiley   +1 more source

Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This study enrolled 70 HER2‐negative, unresectable stage III/IV gastric/gastroesophageal junction adenocarcinoma patients with over 6‐month survival, divided into RNPLS and NPLS groups (n = 35 each). Both groups received 21‐day‐cycle chemotherapy with lobaplatin, nab‐paclitaxel, and S‐1, while RNPLS additionally used ramucirumab.
Juan Wang   +12 more
wiley   +1 more source

Ovarian Carcinoma: Signal Pathways and Clinical Studies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This review synthesizes current knowledge on the pathophysiological mechanisms driven by the Notch, HER2, DNA damage repair (DDR), PI3K/AKT/mTOR, and angiogenesis (VEGF) pathways in ovarian cancer. A key focus is placed on summarizing subsequent targeted therapeutic strategies, detailing the landscape of associated clinical trials and their ...
Yanru Long   +3 more
wiley   +1 more source

1693P Efficacy of corticosteroids in the treatment of chemotherapy-induced thrombocytopenia [PDF]

open access: yesAnnals of Oncology, 2021
A. Sbrana   +5 more
openaire   +1 more source

The Efferocytosis‐Driven Macrophage Polarization: A Concerto in the Tumor Immunosuppressive Microenvironment

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Efferocytosis is a key process for macrophages to clear apoptotic cells, which undergoes the “ Find Me” chemotaxis signal stage, the “eat me” phagocytosis recognition stage and the “digest me” digestion stage in turn. During the aforementioned three stages, various signaling molecules released by apoptotic cells can promote the phenotypic polarization ...
Qiuping Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy